Starpharma Holdings Shares Outstanding 2011-2022 | SPHRY
Starpharma Holdings shares outstanding from 2011 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Starpharma Holdings Annual Shares Outstanding
(Millions of Shares) |
| 2022 |
41 |
| 2021 |
40 |
| 2020 |
37 |
| 2019 |
37 |
| 2018 |
34 |
| 2017 |
37 |
| 2016 |
35 |
| 2015 |
31 |
| 2014 |
28 |
| 2013 |
28 |
| 2012 |
27 |
| 2011 |
|
Starpharma Holdings Quarterly Shares Outstanding
(Millions of Shares) |
| 2022-06-30 |
|
| 2021-12-31 |
|
| 2021-06-30 |
|
| 2020-12-31 |
|
| 2020-06-30 |
|
| 2019-12-31 |
|
| 2019-06-30 |
|
| 2018-06-30 |
|
| 2017-12-31 |
|
| 2017-06-30 |
|
| 2016-12-31 |
|
| 2016-06-30 |
|
| 2015-06-30 |
|
| 2014-12-31 |
|
| 2014-06-30 |
|
| 2013-12-31 |
|
| 2013-06-30 |
|
| 2012-12-31 |
|
| 2012-06-30 |
|
| 2011-12-31 |
|
| 2011-06-30 |
|
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.160B |
$0.004B |
|
Starpharma Holdings Limited is engaged in the development of dendrimer products for pharmaceutical, life science and other applications. The Company's primary product in development is VivaGel, a microbicide gel for women used for the prevention and treatment of bacterial vaginosis and a range of sexually transmitted diseases. It also develops dendrimers as specialty chemicals for industrial applications. Starpharma Holdings Limited is headquartered in Melbourne, Australia.
|
